WCLC 2025 - Posters & ePosters-P1.11.84 Phase II Trial of Tislelizumab Combined With Anlotinib and 2-Cycle Chemotherapy as First-Line Treatment for Advanced NSCLC

P1.11.84 Phase II Trial of Tislelizumab Combined With Anlotinib and 2-Cycle Chemotherapy as First-Line Treatment for Advanced NSCLC

Asset Subtitle

Wen Jun Tang

Meta Tag

Speaker Wen Jun Tang

Topic Metastatic Non-small Cell Lung Cancer – Immunotherapy